Search Videos by Topic or Participant
Browse by Series:

PD-1 Inhibition in Metastatic Renal Cell Carcinoma

Insights From: Prof. Bernard Escudier, MD, Institute Gustave Roussy; Susanne Osanto, MD, PhD, Leiden University Medical Center
Published: Friday, Feb 26, 2016


The phase III CheckMate-025 trial examined whether nivolumab or everolimus was better in second-line treatment of clear cell metastatic renal cell carcinoma (RCC). The results, which were presented at the 2015 European Cancer Congress, showed an overall survival of 25.0 months with nivolumab versus 19.6 months with everolimus. Nivolumab was also well tolerated, notes Susanne Osanto, MD. However, the progression-free survival (PFS) was similar between the two agents. Responses with immunotherapy are somewhat delayed compared with chemotherapy but may continue after treatment is stopped, she notes.

The Check-Mate-025 trial demonstrated that PD-1 inhibition is active in RCC, states Bernard Escudier, MD. As a result of this study, nivolumab will become a standard of care, he believes. The data, so far, show that PD-L1 expression, notes Escudier, is not a reliable predictive marker in RCC. Studies are ongoing that are evaluating frontline nivolumab in combination with another agent, such as a tyrosine kinase inhibitor or another checkpoint inhibitor.
Slider Left
Slider Right


The phase III CheckMate-025 trial examined whether nivolumab or everolimus was better in second-line treatment of clear cell metastatic renal cell carcinoma (RCC). The results, which were presented at the 2015 European Cancer Congress, showed an overall survival of 25.0 months with nivolumab versus 19.6 months with everolimus. Nivolumab was also well tolerated, notes Susanne Osanto, MD. However, the progression-free survival (PFS) was similar between the two agents. Responses with immunotherapy are somewhat delayed compared with chemotherapy but may continue after treatment is stopped, she notes.

The Check-Mate-025 trial demonstrated that PD-1 inhibition is active in RCC, states Bernard Escudier, MD. As a result of this study, nivolumab will become a standard of care, he believes. The data, so far, show that PD-L1 expression, notes Escudier, is not a reliable predictive marker in RCC. Studies are ongoing that are evaluating frontline nivolumab in combination with another agent, such as a tyrosine kinase inhibitor or another checkpoint inhibitor.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x